Kobayashi Pharmaceutical Co., Ltd.
KBYPF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.29 | -13.01 | -0.98 | 1.11 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | 51.05 | 54.56 | 81.51 | 44.84 |
| Quality | ||||
| ROIC | 1.61% | 1.18% | 1.11% | 2.56% |
| Gross Margin | 52.01% | 53.45% | 51.16% | 48.70% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | -11.04% | -1.43% | -1.08% | -0.13% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -6.20 | -8.78 | -11.51 | -5.79 |
| Interest Coverage | 1,616.00 | 0.00 | 0.00 | 1,576.80 |
| Efficiency | ||||
| Inventory Turnover | 0.67 | 0.55 | 0.58 | 1.09 |
| Cash Conversion Cycle | 152.35 | 195.93 | 159.10 | 141.55 |